Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies
Total Page:16
File Type:pdf, Size:1020Kb
Author Manuscript Published OnlineFirst on November 20, 2020; DOI: 10.1158/2159-8290.CD-20-0766 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib Ian M. Silverman,1 Antoine Hollebecque,2 Luc Friboulet,2 Sherry Owens,1 Robert C. Newton,1 Huiling Zhen,3 Luis Féliz,4 Camilla Zecchetto,5 Davide Melisi,5 and Timothy C. Burn1 1Incyte Research Institute, Wilmington, Delaware. 2Institut Gustave Roussy, Villejuif, France. 3Incyte Corporation, Wilmington, Delaware. 4Incyte Biosciences International Sàrl, Morges, Switzerland. 5Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Università degli Studi di Verona, Verona, Italy. Running Title: Genomic Profiling in FGFR2-Rearranged Cholangiocarcinoma Keywords: pemigatinib, FGFR2, precision medicine, genomic profiling, cholangiocarcinoma Additional Information Financial Support: This study was sponsored by Incyte Corporation (Wilmington, Delaware). Corresponding Author: Timothy C. Burn, 1801 Augustine Cut-Off, Wilmington, DE 19803 W: 302 498 6787; [email protected] Conflict of Interest: 1 Downloaded from cancerdiscovery.aacrjournals.org on September 30, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 20, 2020; DOI: 10.1158/2159-8290.CD-20-0766 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. I.M. Silverman has employment with and owns stocks from Incyte Corporation. A. Hollebecque is a paid consultant for Debiopharm and Incyte Corporation. L. Friboulet received research funding from Debiopharm. S. Owens has employment with and owns stocks from Incyte Corporation. R.C. Newton had employment with Incyte Corporation at the time of this work and owns stock from Incyte Corporation. H. Zhen has employment with and owns stocks from Incyte Corporation. L. Féliz has employment with and owns stocks from Incyte Corporation. C. Zecchetto declares no potential conflicts of interest. D. Melisi received research funding from Celgene, Evotec, Incyte Corporation, and Shire; and had a consulting role at Baxter, Eli Lilly, Evotec, iOnctura, and Shire, which was unrelated to the present work. T.C. Burn has employment with and owns stocks from Incyte Corporation. 2 Downloaded from cancerdiscovery.aacrjournals.org on September 30, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 20, 2020; DOI: 10.1158/2159-8290.CD-20-0766 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Pemigatinib, a selective fibroblast growth factor receptor (FGFR) 1–3 inhibitor, has demonstrated antitumor activity in FIGHT-202, a phase 2 study in patients with cholangiocarcinoma harboring FGFR2 fusions/rearrangements, and has gained regulatory approval in the United States. Eligibility for FIGHT-202 was assessed using genomic profiling; here, these data were utilized to characterize the genomic landscape of cholangiocarcinoma, and to uncover unique molecular features of patients harboring FGFR2 rearrangements. The results highlight the high percentage of patients with cholangiocarcinoma harboring potentially actionable genomic alterations and the diversity in gene partners that rearrange with FGFR2. Clinicogenomic analysis of pemigatinib-treated patients identified mechanisms of primary and acquired resistance. Genomic subsets of patients with other potentially actionable FGF/FGFR alterations were also identified. Our study provides a framework for molecularly-guided clinical trials and underscores the importance of genomic profiling to enable a deeper understanding of the molecular basis for response and nonresponse to targeted therapy. 3 Downloaded from cancerdiscovery.aacrjournals.org on September 30, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 20, 2020; DOI: 10.1158/2159-8290.CD-20-0766 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Statement of Significance We utilized genomic profiling data from FIGHT-202 to gain insights into the genomic landscape of cholangiocarcinoma, to understand the molecular diversity of patients with FGFR2 fusions or rearrangements, and to interrogate the clinicogenomics of patients treated with pemigatinib. Our study highlights the utility of genomic profiling in clinical trials. 4 Downloaded from cancerdiscovery.aacrjournals.org on September 30, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 20, 2020; DOI: 10.1158/2159-8290.CD-20-0766 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. INTRODUCTION Cholangiocarcinoma is the most common primary malignancy of the bile duct, and accounts for 3% of all gastrointestinal tumors (1,2). Cholangiocarcinoma comprises a group of heterogeneous tumors categorized as intrahepatic and extrahepatic (perihilar and distal), based on biliary tract location (2). Incidence and mortality rates of cholangiocarcinoma have increased over the past decades, most notably for intrahepatic cholangiocarcinoma (3-5). The prognosis of patients with cholangiocarcinoma is poor; surgery is the only potentially curative therapeutic option (6). However, as most patients present with advanced disease, only approximately one-third of newly diagnosed patients qualify for surgery. Among patients who are qualified to undergo potentially curative resection, most (~76%) will experience a relapse within 2 years (7). For patients with locally advanced or metastatic disease, the standard-of-care first-line systemic treatment is chemotherapy with gemcitabine plus cisplatin (8). There is no established standard of care following first-line chemotherapy failure, and second-line chemotherapy shows limited efficacy in patients with advanced biliary tract cancer (9-11). Genomic profiling, based on next-generation sequencing (NGS) of a panel of genes known to be altered in cancer, allows for the simultaneous detection of numerous genomic alteration types, including mutations, copy number alterations, and fusions or rearrangements (12). Therefore, this technique provides a powerful basis for guiding choice of targeted therapy, improved diagnosis, and identification of prognostic and predictive biomarkers. Genomic analysis of patients with cholangiocarcinoma has revealed alterations of targetable oncogenes in almost 50% of patients (13), with recurrent alterations in IDH1 and FGFR2 occurring almost exclusively in patients with intrahepatic cholangiocarcinoma compared with extrahepatic cholangiocarcinoma (13-15). Specifically, FGFR2 fusions or rearrangements are observed in 5 Downloaded from cancerdiscovery.aacrjournals.org on September 30, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 20, 2020; DOI: 10.1158/2159-8290.CD-20-0766 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 10% to 16% of patients with intrahepatic cholangiocarcinoma (16-18). FGFR2 genomic alterations (GAs), including activating point mutations, fusions, and rearrangements, are known oncogenic drivers and provide a molecular signature to identify patients who may benefit from inhibition of FGFR2 tyrosine kinase activity (19,20). Therefore, NGS-based assays are used to comprehensively identify patients with cholangiocarcinoma that may benefit from targeted therapies. Pemigatinib is the first targeted therapeutic agent approved in the United States for use in cholangiocarcinoma with FGFR2 fusions or rearrangements. Pemigatinib is a selective, potent, oral, competitive inhibitor of FGFR1, 2, and 3 that inhibits receptor autophosphorylation and subsequent activation of FGF/FGFR-mediated signaling networks, leading to an inhibition of tumor cell growth in FGFR-driven cancers (21). The FIbroblast Growth factor receptor inhibitor in oncology and Hematology Trial (FIGHT-202; NCT02924376) is a phase 2, multicenter, open- label study of pemigatinib monotherapy in previously treated patients with locally advanced, metastatic, or surgically unresectable cholangiocarcinoma, including patients with FGFR2 fusions or rearrangements (22). In this study, patients were initially prescreened prior to enrollment for FGF/FGFR alterations including amplifications, mutations, fusions, or rearrangements. The primary analysis of 107 patients included only patients harboring FGFR2 fusions or rearrangements. In these patients, pemigatinib monotherapy resulted in an independent centrally confirmed objective response rate (ORR) of 35.5% and a disease control rate of 82%. With a median follow-up of 15.4 months, responses were durable, with a median duration of response of 7.5 (95% confidence interval [CI], 5.7−14.5) months. Median progression-free survival (PFS) was 6.9 (95% CI, 6.2–9.6) months. 6 Downloaded from cancerdiscovery.aacrjournals.org on September 30, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 20, 2020; DOI: 10.1158/2159-8290.CD-20-0766 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. There is significant molecular diversity of FGFR2 fusions and rearrangements in